Search PubMed⌕ Search

Biomedical subjects

G Garotta

Publications and source records attributed to G Garotta.

94 records · Page 6Linked to original sources
PubMedDate not supplied

Development of interferon-gamma antagonists as an example of biotechnology application to approach new immunomodulators.

Recent applications of recombinant DNA technology have made possible the isolation and structural characterization of previously poorly-described proteins (e.g. Interferon-gamma (IFN gamma) and its specific receptors). These "recombinant proteins" can be developed as new therapeutics, or used in high specific screening. Structural information obtained from the studies on the recombinant proteins and their receptors, can then be used in computer assisted molecular modeling to design non-proteinaceous immunomodulatory, antiinflammatory and antineoplastic molecules. These novel compounds, able to modulate the functions of the endogenous IFN gamma, will show several advantages in respect to the recombinant proteins used as drugs. We would like to illustrate how the application of the modern biotechnology leads to the development of new drugs and, as an example, to describe the procedure which is followed in the case of the IFN gamma.

Adjuvants, Immunologic↗
PubMedDate not supplied

A simple, rapid and large capacity ELISA for biologically active native and recombinant human IFN gamma.

A rapid and sensitive enzyme-immunoassay for native and recombinant human interferon gamma is described. The test is performed in one step at room temperature and is based on the sandwich principle. The IFN gamma preparation is distributed with horse radish peroxidase-labeled monoclonal antibody to IFN gamma in microtiter plates previously coated with a second mab against IFN gamma. The amount of the IFN gamma mab sandwich fixed in the microtiter plate wells is proportional to the color developed after the addition of peroxidase-specific substrate. The two mab's used in the test neutralize IFN gamma and are directed against the same epitope. For this reason they can only detect the biologically active dimeric form of IFN gamma. The IFN gamma-ELISA works in phosphate buffer as well as in tissue culture medium or human serum. As the assay is routinely performed in 2 hours, the limit of detection is 3 U/ml of IFN gamma (0.3 ng/ml). If the assay is performed in 16 hours, the limit of detection decreases to 0.5 U/ml IFN gamma (0.06 ng/ml). The conditions to preserve the activity of IFN gamma preparation as standard are discussed.

Antibodies, Monoclonal↗
PubMedDate not supplied

Serum amyloid protein (SAP) as a marker of autoimmune disease in mice.

Acute phase proteins are good markers of inflammatory processes. To clarify whether Serum Amyloid Protein (SAP) can be a marker for the onset of SLE disease in mice, we measured constitutive and inducible SAP levels in normal mice of different strains, in C57Bl/6 lpr/lpr (B6lpr) and [NZB x NZW]F1 (NZB/W) SLE-prone mice, in mice that develop Lupus-like syndrome during chronic Graft versus Host (GvH) reaction and in mice suffering acute GvH reaction. In comparison to B6lpr, NZB/W mice showed higher blood levels of SAP but those levels did not correlate with autoimmune parameters. In B6lpr, the SAP levels steadily increased with age and correlated with some of the parameters used for monitoring the SLE disease. High levels of SAP were also found in mice suffering acute GvH reaction whereas the lupus-like chronic GvH disease was associated with limited increase of SAP levels.

Age of Onset↗